On Tuesday, President Donald Trump announced a $70 billion deal with drug manufacturer Pfizer claiming that this unconstitutional theft of taxpayer dollars will lower drug prices for Americans. The White House describes it as part of a broader initiative, and intends to include other drugmakers in the near future.
Pfizer brags that the agreement makes it possible for the company “to fully focus on delivering the next generation of cures … in areas like oncology, obesity, vaccines, and inflammation and immunology.” (Emphasis added.)
Deadly Jabs
Is this something we want to happen, knowing that people who got the Pfizer jab face a 37 percent higher risk of death than those who received Moderna injections? That’s according to research published in April by MIT Professor Retsef Levi and Florida Surgeon General Dr. Joseph Ladapo.
In fact, as McCullough Foundation epidemiologist Nicolas Hulscher explains, “Among 1.47 million Florida adults, those who received Pfizer’s BNT162b2 vaccine had higher 12-month risks of all-cause, cardiovascular, COVID-19, and non-COVID-19 mortality.” And Vaccine Safety Research Foundation founder Steve Kirsch further analyzed the data in the Levi/Ladapo study to determine that “the Pfizer vaccine likely killed over 500,000 Americans.”
Nevertheless, during a Newsmax interview, U.S. Food and Drug Administration Commissioner Marty Makary called Tuesday an “historic day” for American healthcare. Earlier that day, during a press conference announcing the deal, there was much back-slapping sycophancy exchanged between him, Pfizer CEO Albert Bourla, President Trump, healthy lifestyle guru-turned-Centers for Medicare & Medicaid Services administrator Mehmet Oz, and Health and Human Services Secretary Robert F. Kennedy, Jr., the reputed Big Pharma fighter and MAHA leader:
Motivated by Tariffs
Pfizer intends to invest its $70 billion grift in research and development and domestic manufacturing while it lowers prices in the U.S. market on some of its products. Meanwhile, Trump is extending a three-year grace period during which Pfizer products will not be subject to pharmaceutical-targeted tariffs, “as long as, of course, we move the products here,” Bourla said.
Reuters added some interesting details:
Pfizer will be part of the White House’s new direct-to-consumer website for Americans to buy drugs, called TrumpRx, that will launch in 2026.
Several drugmakers have already set up direct-to-consumer pricing for some of their drugs, to be listed on a new website from the U.S. lobby group PhRMA, and raised the prices of their therapies in Britain in line with Trump’s desire to offset price decreases in the U.S.
On September 25, Trump announced he would impose a 100% tariff on imports of branded or patented pharmaceutical products from October 1, unless a drugmaker is building a manufacturing plant in the U.S.
So, Pfizer gets to use $70 billion of taxpayer money to expand its U.S. manufacturing of poisons for the American public while enjoying exemption from the new 100-percent tariffs imposed on its non-domestic competitors.
Corporate Cronyism?
“This deal benefits nobody,” writes Big Pharma expert Sasha Latypova on her Substack. “Yes, it will provide contracts for construction, equipment and some jobs (very few given automation levels in drug manufacturing) but it chains all the local authorities to enforcing the ‘next con-demic’ and other deadly nonsense they have in the pipeline. In other words, they want to pay local communities to poison our children in exchange for ‘jobs’.”
Moreover, Latypova points out, last year Pfizer was planning a direct-to-patient online portal. She wonders whether TrumpRx is that platform, speculating that “they planned the website and then sent lobbyists to regulators at the Trump admin,” and that the deal means “gigantic kickbacks for the Trump Organization.” She estimates that “Pfizer may funnel up to ~$500M” to that wealthy venture capital corporation through TrumpRx.
